Paloma Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Paloma Partners’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,758	Closed	-$248K	–	1923
2019 Q2	$248K	Sell	11,758 -6,473	-36%	-$135K	﹤0.01%	1408
2019 Q1	$373K	Buy	+18,231	New	+$408K	0.01%	1207
2018 Q4	–	Sell	-11,600	Closed	-$223K	–	1249
2018 Q3	$223K	Buy	+11,600	New	+$207K	﹤0.01%	1348
2018 Q1	–	Sell	-10,261	Closed	-$197K	–	1913
2017 Q4	$197K	Buy	+10,261	New	+$192K	﹤0.01%	1744
2017 Q3	–	Sell	-24,680	Closed	-$441K	–	2073
2017 Q2	$441K	Sell	24,680 -34,066	-58%	-$540K	0.01%	1617
2017 Q1	$852K	Buy	58,746 +27,884	+90%	+$438K	0.01%	1323
2016 Q4	$568K	Buy	+30,862	New	+$600K	0.01%	1460

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners's AMPH Position: Q3 2019 in Review

Paloma Partners sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2019, closing a stake of 11,758 shares — an estimated $248K sold.

Paloma Partners first reported a position in AMPH in Q4 2016 and held it in 7 quarters. The position peaked at $852K in Q1 2017. 134 funds tracked by Wall St. Rank hold AMPH as of Q3 2019.

Paloma Partners reported no remaining Amphastar Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 11,758 Amphastar Pharmaceuticals shares in Q3 2019, an estimated $248K.
Paloma Partners first reported a position in Amphastar Pharmaceuticals in Q4 2016 and held it in 7 quarters.
Paloma Partners's Amphastar Pharmaceuticals position peaked at $852K in Q1 2017.
134 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.